Loading page…
Healthcare
Roivant Sciences Ltd., categorized in Healthcare, holds an AlphaScore of 22/100 and an Avoid signal. The October 11, 2026 snapshot displays a debt-to-equity ratio of 0.02 and a revenue growth figure of -71.57%. A key strength is the minimal debt-to-equity ratio, indicating a very clean balance sheet with low leverage risk. The primary risk is the drastic contraction in sales shown by the negative revenue growth. Evidence is limited exclusively to this record.
Written 11/10/2026, 00:34:08 UTC · Snapshot 11/10/2026